Beihai Gofar Chuanshan Biological Co. Ltd. Class A

Beihai Gofar Chuanshan Biological Co. Ltd. Class A

SSSE:600538
4.26
CNY
-0.16
(-3.62%)
-0.16EPS
2.51BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A carries a market capitalization of 2.51B, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.51B
Enterprise Value2.49B

Share Statistics

As of September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A has 524.20M shares outstanding.

Shares Outstanding524.20M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 8.04, and the price-to-book ratio stands at 3.82.

PS Ratio8.04
PB Ratio3.82
P/TBV Ratio4.52

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 7.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.49B versus a market cap of 2.51B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.18

Financial Position

As of September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A maintains a current ratio of 3.74, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.22, indicating elevated leverage, while an interest coverage ratio of -37.33 demonstrates limited ability to service its debt obligations.

Current Ratio3.74
Quick Ratio0.75
Debt / Equity10.22
Debt / EBITDA-0.77
Interest Coverage-37.33

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A posted a negative return on equity (ROE) of -12.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.06, reflecting losses generated across the asset base. The company generates approximately 791,103.63 in revenue per employee across its workforce of 438.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.05 indicates how many times Beihai Gofar Chuanshan Biological Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-12.79
Return on Assets (ROA)-10.06
Revenue Per Employee791,103.63
Employee Count438.00
Inventory Turnover3.05

Taxes

CNY

Over the twelve months ended September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A recorded 1.96M in income tax expense. The company reported a pretax loss of -88.72M and -91.26M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax1.96M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A's stock has declined approximately 28.64% over the past 52 weeks. The 50-day moving average sits at 4.65, while the 200-day moving average is 5.75.

52-Week Price Change-28.64%
50-Day Moving Average4.65
200-Day Moving Average5.75

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A generated 346.50M in revenue and converted that into -91.26M in net income, yielding earnings per share of -0.16. EBITDA reached -88.74M, while operating income came in at -15.44M.

Revenue346.50M
Gross Profit82.29M
Operating Income-15.44M
Pretax Income-88.72M
Net Income-91.26M
EBITDA-88.74M
EBIT-88.74M
Earnings Per Share (EPS)-0.16

Balance Sheet

CNY

As of September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A holds 100.17M in cash and equivalents against 68.06M in total debt, resulting in a net debt position of -65.21M. Total book value stands at 657.77M, with working capital of 363.94M providing operational flexibility.

Cash & Cash Equivalents100.17M
Total Debt68.06M
Net Debt-65.21M
Equity (Book Value)657.77M
Book Value Per Share1.25
Working Capital363.94M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-6.21M

Margins

Over the twelve months ended September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A posted a gross margin of 23.75, reflecting its pricing power and cost economics. The operating margin of -4.46 and net profit margin of -26.34 provide insight into operational efficiency.

Gross Margin23.75
Operating Margin-4.46
Pretax Margin-25.61
Profit Margin-26.34
EBITDA Margin-25.61

Dividends & Yields

Over the twelve months ended September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.58 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Beihai Gofar Chuanshan Biological Co. Ltd. Class A shareholders.

Payout Ratio-0.58
Shareholder Yield0.38

Stock Splits

Beihai Gofar Chuanshan Biological Co. Ltd. Class A's most recent stock split took place on June 7, 2006 with a 5:7 split ratio.

Last Split Date6/7/2006
Split Ratio5:7

Scores

As of September 30, 2026, Beihai Gofar Chuanshan Biological Co. Ltd. Class A has an Altman Z-Score of 7.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.30